Quarterly report pursuant to Section 13 or 15(d)

Note 1 - Business

v3.19.3
Note 1 - Business
9 Months Ended
Sep. 30, 2019
Notes to Financial Statements  
Business Description and Basis of Presentation [Text Block]
1.
Business
 
DiaMedica Therapeutics Inc. and its wholly-owned subsidiaries, DiaMedica USA, Inc. and DiaMedica Australia Pty Ltd. (collectively “we,” “us,” “our,” “DiaMedica” and the “Company”), exist for the primary purpose of advancing the clinical and commercial development of a proprietary recombinant, or synthetic,
KLK1
protein for the treatment of kidney and neurological diseases with our primary focus on chronic kidney disease (“CKD”) and acute ischemic stroke (“AIS”). Our parent company is governed under the British Columbia Business Corporations Act and, commencing on
December 7, 2018,
our common shares are publicly traded on The Nasdaq Capital Market under the symbol “DMAC.” The Company’s shares were previously traded on the TSX Venture Exchange in Canada and on the OTCQB in the United States.